CD20
3 EU-approved indications of 1 drug need a CD20 result, in 2 tumour types, most of them in large B-cell lymphoma and other B-cell lymphoma.
Approved indications3
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| Large B-cell lymphoma2 | ||||
MabThera | + chemotherapy | 1L advanced | DLBCL only; Children and adolescents only; Aged 6 months to less than 18 years old | |
MabThera | + CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) | Any line | DLBCL only | |
| Other B-cell lymphoma1 | ||||
MabThera | + chemotherapy | 1L advanced | Children and adolescents only; Aged 6 months to less than 18 years old | |
CD20 by tumour
Label wording3
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Rituximab (MabThera)
MabThera is indicated for the treatment of adult patients with CD20 positive diffuse large B-cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
- Rituximab (MabThera)
MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged 6 months to less than 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).
- Rituximab (MabThera)
MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged 6 months to less than 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).